Amanote Research
Register
Sign In
81 Outcomes of Multi-Target Therapy Using Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis
doi 10.1136/lupus-2017-000215.81
Full Text
Open PDF
Abstract
Available in
full text
Date
March 1, 2017
Authors
CB Choi
S Won
HH Kwon
SW Nam
SC Bae
Publisher
Lupus Foundation of America
Related search
Cyclophosphamide Versus Mycophenolate Mofetil for Initial Treatment of Lupus Nephritis
Kidney International
Nephrology
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis
Clinical Journal of the American Society of Nephrology
Epidemiology
Nephrology
Critical Care
Transplantation
Intensive Care Medicine
Outcomes Following Mycophenolate Mofetil Versus Cyclophosphamide Induction Treatment for Proliferative Juvenile-Onset Lupus Nephritis
Lupus
Rheumatology
Efficacy of High-Dose Mycophenolate Mofetil in Multitarget Therapy for Lupus Nephritis: Two Consecutive Case Reports
Cureus
Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Childhood-Onset Proliferative Lupus Nephritis
Arthritis Care and Research
Rheumatology
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-Line Therapy for Patients With Autoimmune Hepatitis
Clinical Gastroenterology and Hepatology
Hepatology
Gastroenterology
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study
American Journal of Kidney Diseases
Nephrology
Mycophenolate Mofetil Induced Remission in Steroid-Refractory Autoimmune Hemolytic Anemia
Meandros Medical and Dental Journal
Mycophenolate Mofetil Reduces STAT3 Phosphorylation in Systemic Lupus Erythematosus Patients
JCI insight
Medicine
